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Chemoresistance to conventional cytotoxic drugsmay occur in any type of cancer and this can either be inherent or develop through
time. Studies have linked this acquired resistance to the abnormal expression of microRNAs (miRNAs) that normally silence genes.
At abnormal levels, miRNAs can either gain ability to silence tumour suppressor genes or else lose ability to silence oncogenes.
miRNAs can also affect pathways that are involved in drugmetabolism, such as drug effluxpumps, resulting in a resistant phenotype.
The scope of this review is to provide an introspective analysis on the specific niches of breast carcinoma and neuroblastoma
research.
1. Introduction
Carcinogenesis is a dynamic process in the cell genome
involving multifactorial steps [1]. Six distinct changes are
observed in generalmalignant growth that drives the progres-
sive transformation of normal human cells into invasive cells
[2]. The onset of this internal potential for self-proliferation
is the result of the mutation of particular genes that are
responsible of cell growth [3, 4]. The alteration in the normal
genetic material consequently causes errors in the cell cycle.
This induction occurs as the genes that are mutated encode
proteins that usually progress the cell cycle orderly [3].
Cancer develops as the independent growth is insensitive
to antigrowth factors or environmental signals. CD44 cell
surface molecule, normally involved in the cell-to-cell inter-
action [5], is evidently observed to decrease in neuroblastoma
development [6]. The results of impaired cell motility are
inability of induction of apoptosis and cell cycle arrest. Col-
lectively these features lead to limitless replication potential
followed by the intrinsic ability to encourage angiogenesis [7].
2. Breast Cancer Development
Similar to other solid tumours, development of breast cancer
occurs through a combination of epigenetic changes and the
molecular aberrations mentioned earlier [8]. Breast cancer
is the most commonly diagnosed malignancy and the major
cause of death amongst women worldwide [9]. It is con-
sidered to be a highly heterogeneous disease [10] since it
may develop due to varying molecular features and clinically
presents itself in diversemanners [11]. Twomajor gene classes
are crucially linkedwith the development of breast cancer and
are described below.
2.1. HER-2 Gene. Tyrosine kinases are proteins which serve
as mediators of cell signaling pathways, affecting both cell
survival and growth [12]. A classical type of these receptor
tyrosine kinases is the erythroblastic leukemia viral oncogene
homolog (ErbB) family of receptors, which includes four
subfamilies: the ErbB or the human epidermal growth factor
receptors (HER-1 to HER4, or ErbB-1 to ErB-4) [13]. All of
these receptors are crucial for orchestrating the proliferation
and differentiation of normal cells and can therefore regulate
growth [14]. Each receptor is composed of three structural
domains: a cytoplasmic area for tyrosine kinase receptor, a
transmembrane domain, and an extracellular binding site for
ligands [15]. Mutations in this family of receptors tend to
be of a somatic type, such that the abnormality occurs after
conception, rather than passed on through the family [16].
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Observably, anomalous activity of a particular receptor
within this family, HER-2, has been identified in approxi-
mately 20–30% of breast cancer cases [8, 13]. This receptor
is encoded by the HER-2 protooncogene located on chro-
mosome 17q [14]. Growth factor receptors become activated
upon ligand binding and receptor dimerization [13]. The lat-
ter can either be heterodimerization, which occurs between
two receptors of the same family, or homodimerization,
which occurs between two identical receptors [17]. This
dimerization process helps to activate the tyrosine kinase
segment of the receptor which results in the phosphorylation
ofmultiple tyrosine residues [15].These createmultiple trans-
duction pathways acting on downstream receptor proteins
which finally cause the physiologic responses that had been
previously signaled, such as cell division and apoptosis [17].
Such pathways include the 3-kinase (PI3K)/Akt pathways and
mitogen-activated protein (MAP) kinase [8].
This process is often dysregulated in breast cancer, where
amplification of the HER-2 protooncogene results in overex-
pression of the receptor which fuels excessive cellular pro-
liferation and invasiveness and can also affect drug resistance
pathways [13]. In essence, genetic anomalies alter the HER-2
protooncogene into an oncogene through a gain-of-function
role that stimulates excessive cellular division, creating dis-
proportionate cellular growth. The mutations causing this
type of oncogenic change are usually of the dominant type,
such that a mutation in just one allele may disrupt the whole
reproductive program of the cells [18].
2.2. BRCA Genes. Besides abnormalities in protooncogenes,
the genes that examine the cell cycle at specified checkpoints
can be mutated and result in carcinogenesis. Mutations in
these tumour suppressors are found in a spectrum of cancer
models, including breast cancer. A particular set of tumour
suppressors associatedwith breast cancer is the Breast Cancer
1 and 2 gene set (BRCA1 and BRCA2) [19]. Similar to other
tumour suppressors, the product expressed from this family
of genes helps to mediate the rate of the cell cycle [20].
Various studies indicated that germ-line mutations in these
genes were linked to an increased chance of developing breast
cancer [21–24]. In 1990, DNA linkage studies testing family
members with similar features, such as early onset of breast
cancer and familial history of both breast andovarian cancers,
were carried out [22]. The first gene found to be abnormally
expressed was the BRCA1, located on chromosome 17 [22].
Further studies continued until four years later, when a
similar gene on chromosome 13 was also found to bemutated
in patients presenting with similar clinical symptoms and,
consequently, this novel gene was named BRCA2 [22]. In
addition, both mutations in these genes are inherited in an
autosomal dominant pattern [22].
Both of these genes code for proteins which are responsi-
ble for the regulation of genomic stability, ranging fromDNA
damage response and repair to apoptosis [25]. BRCA1 gene is
related to having a specific role in regulating transcription,
cell cycle, and DNA damage [25]. In a study carried out by
Scully et al., this association has been supported since the
BRCA1 resultant protein can interact with the basal tran-
scriptional machinery of a cell, including RNA polymerase
II and transcription factors [26]. The role of BRCA1 protein
as a tumour suppressor became even more evident with its
role in the intensification of the centrosome and at the G
2
/M
checkpoints of the cell cycle [27]. The centrosome is a vital
organelle which regulates the association of microtubules
which helpsmaintain cell structure andpolarity, coordinating
the development of the mitotic spindle [28]. Specifically, Hsu
and White had validated that the BRCA1 tumour suppressor
can form a link with 𝛾-tubulin, a critical protein within
the centrosome [27]. Its association with 𝛾-tubulin and the
centrosome confers evidence that the BRCA1 plays a crucial
role in the orderly regulation of themitotic spindle formation
and the G
2
/M checkpoint [29]. Consequently, suppressed
BRCA1 expression, which commonly occurs in cancer cells,
results in abnormally hastened cellular proliferation. This
has been verified in a study by Thompson et al., where
aggressive cellular proliferation of mammary cells was noted
after experimentally inhibiting BRCA1 expression with the
use of antisense oligonucleotides [30].
Nonetheless, despite the variation of their protein se-
quence, both BRCA1 and BRCA2 have mutual biological
roles [31]. Both genes have significant presence in both
mitotic and meiotic cells [32], where the proteins expressed
by these genes are related to Human RAD51 [33]. It has
been ominously found that this has a fundamental role
in homologous recombination and DNA double-stranded
break repair [34, 35]. Various studies validated that the mes-
senger RNA (mRNA) expression of both BRCA1 and BRCA2
genes escalates as the cell moves into S phase, ascertaining
that their biological functions culminate during (or after)
DNA replication [36–38]. This protein, Human RAD51,
is vital in homologous recombination [25] and in repair-
ing double-stranded DNA breaks by amalgamating single-
stranded DNA, resulting in a nucleoprotein filament which
has the potential to occupy a homologous duplex DNA mol-
ecule [39]. This provides evidence that both BRCA1 and
BRCA2 assist in a damage response pathway. Consequently,
aberrant functional behavior silencing the roles of BRCA1
and BRCA2 will result in irregular DNA structures.
Considering that breast cancer is claimed to be a hetero-
geneous disease, an association between both environmental
and genetic elements definitely has a role in its formation
[25]. Although mutations in HER-2 and BRCA genes tend
to be the most commonly studied abnormalities, other genes
and receptors have also been found to induce breast cancer.
These mainly include the tumour protein 53, phosphatase
and tensin homolog gene, and the mitogen-activated protein
kinase kinase kinase-1 which is associated with a slimmer
chance to induce breast cancer [40, 41].
2.3. Clinical Presentation. Initially, breast cancer exhibits no
symptoms as the growthmight be too small and undetectable,
yet highly curable. Patients usually present to a clinician after
a physical, painless lump is detected around the breast area.
In less frequent cases, the presence of a lump is accompanied
by breast pain or noticeable changes in the breast, such as
redness, abnormal nipple discharge such as blood, or sensitive
tenderness [42]. Diagnostic tests are initially noninvasive,
where the contour of the lump can be felt either by palpable
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Table 1: Classification of the different breast cancer subtypes and their most commonly associated molecular features and their related
prognosis.
Breast cancer subtype Molecular features Clinical outcomes References
Luminal A ER+ and/or PR, HER2− Stage I [149]
Luminal B ER+ and/or PR+, HER2+ Stage I (III also reported) [149, 150]
HER2-enriched ER− and/or PR−, HER2+ Mostly stage III [149, 150]
Basal-like subtype or triple-negative ER− and/or PR−, HER2−, BRCA1 Mostly stage III [149–151]
ER: estrogen receptor, PR: progesterone receptor, HER: human epidermal growth factor receptor, and BRCA: breast cancer genes; + indicates the presence of
the receptor; − indicates the absence of the receptor.
examination or by radiographic methods such as mammog-
raphy or ultrasound. At this point, the clinician must deduce
whether the lump is benign or if amalignancy is suspected. In
queried cases, a biopsy from the breast is collected via needle
or surgical incision, where microscopic analysis of the tissue
can establish the nature of the growth [43]. Apart from an
initial diagnosis, microscopic results also establish the extent
of the malignancy and the pattern of the growth. In cases
resulting as positive for breast cancer, further tests are carried
out to identify the type of malignancy [43].
A breast malignancy can start developing either in the
ducts or in the lobules, thereby termed as a ductal or lobular
breast carcinoma, respectively (DCIS or LCIS), and in less
common cases from the stromal tissues of the breast [44].
Each type of breast cancer has been classified throughout
the years by gene expression profiling which classifies breast
cancer into different molecular subtypes, as explained in
Table 1.
Molecular markers are recently being highly utilized to
deduce the presence or absence of estrogen receptors, pro-
gesterone receptors, and human epidermal growth factor
receptor in breast cancer [45].
The subdivision of the type of malignancy is critically
important when prescribing treatment, as one therapeutic
measure can be highly effective for one breast cancer subtype,
yet barely effective in other subtypes [45].
2.4. Breast Cancer Therapies. In 2012, 1.7 million cases of
breast cancer were diagnosed on a global scale [46]. It is
believed that one-third of breast cancer mortality rates can
be reduced through earlier malignancy screening imple-
mentation and therefore allowing for more prompt optimal
treatment initiation [47].
The selected treatment is primarily based on the staging
and/or grading of the phenotypic characteristics of themalig-
nancy [48]. Consequently, accurate microscopic screening
has a significant effect on the outcome of the patient as the
staging determines the treatment protocol.Other factors such
as risks and benefits, age of the patient, and the patient’s
predicted compliance to the proposed therapy also influence
treatment decisions [48].
Staging of an individual tumour depends on the charac-
teristics observed during clinical examination or else during
the pathological stage that deals with the features observed
after surgery [49]. Pathological staging is themost commonly
implemented measure as it gives a more accurate prognosis
[49]. International criteria staging the features of the tumour
cells are utilized worldwide, following the stages indicated
by the American Joint Committee on Cancer (AJCC) TNM
system [49]. The staging levels are concluded by combining
the tumour size (T), the degree of metastasis into lymph
nodes neighbouring the breast (N), and metastasis into other
organs (M) [49].
Histological grading is the overall score established upon
microscopic evaluation of both morphological and cytologi-
cal features of the cancerous cells [50]. The grading provides
information regarding the prognosis while staging sheds light
on the overall progression of the cancer.
Depending on the tumour grade/stage and the molecular
characteristics of the malignancy, treatments vary, ranging
from surgery, chemotherapy, radiation, hormonal, and tar-
geted therapy [51]. Chemotherapy is the most commonly
used treatment where it is also utilised with other therapies
and even after surgery [10]. The simultaneous employment
of multiple therapeutic measures has effectively improved
the rate of breast cancer survival. Nonetheless, a completely
effective response to chemotherapy is still highly limited in
the majority of cases [52]. Consequently, it is noted that
initially most of the patients respond effectively to chem-
otherapy, though this response is highly reduced after a set
drug exposure time period that varies between individual
patients. Furthermore, various studies demonstrated that
a subgroup of patients is inclined [53, 54]. One study in
particular carried out by Brewster et al. confirmed that breast
cancer recurrence rates were 11% after 5 years and 20% after 10
years of therapy [54]. This variation in treatment response is
believed to be in part due to the tumour developingmolecular
mechanisms of resistance to chemotherapeutic drugs [55].
3. Neuroblastoma
Neuroblastoma is an aggressive tumour growth of the pri-
mordial cells of the sympathetic nervous system. It is themost
common solid extracranial neoplasm embryonal tumour
[56]. This growth arises during foetal or early postnatal
life and is remarkable for its spontaneous regression or
maturation, regardless of the treatment [57, 58]. This disease
heterogeneity can display a very aggressive,malignant pheno-
type that is weakly sensitive to present intensive multimodal
therapy [57]. Neuroblastoma presents with dynamic genetic
variations, as exhibited in most human cancer developments,
which influences the combination of the therapy given to
the patient [59]. The degree of aggressiveness and risk
of regression of neuroblastoma are sorted into groups for
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better classification [60]. The risk stratification, age, and the
complex genetic pattern of the disease collectively contribute
to the regression or progression of this malignancy [56–58].
3.1. Incidence. Neuroblastoma presents approximately 100
new cases per year in UK as quoted fromTheNeuroblastoma
Society (UK) [61]. Evidence in the research by the SEER
Cancer Statistics, based in USA, indicates that the incidence
rate of neuroblastoma in children less than a year old is of
51.5 per 1,000,000 subjects.This study was age-adjusted to the
2000 US Std Population (19 age groups, Census P25-1130),
from which patients being of age one or less add to 40% of
all the diagnosed cases [62]. The median age of diagnosis
of neuroblastoma is of 18-19 months [58, 59, 63] where it
represents 8% of all malignancies diagnosed in paediatric
patients younger than 15 years [64]. Furthermore, in more
recent data neuroblastoma was the causal death of 15% of the
diagnosed patients in 2006 [65].
3.2. Clinical Presentation. Most neuroblastoma tumours
present with undifferentiated sympathetic nerve cells arising
from the neural crest [57]. Presenting signs and symptoms are
highly variable including fatigue, unexpected fever, weight
loss, irritability, and bone pain [66]. Furthermore, signs
vary depending on the site at which this primary tumour
occurs and also whether metastasis had developed or not
[66]. In most cases of primary tumour, the patient presents
malignant growth in the abdomen region, where at least half
of these arise from the adrenal medulla. Next common sites
involve the neck, chest, and pelvis [58]. Around 40% of the
patients present with localized disease, albeit in majority of
neuroblastoma cases metastasis to the lymph nodes, bone
marrow, bone, liver, and skin occurs [58]. With a small
percentage of 5% of the patients, a striking phenotype of 4S
disease is observed, where these infants develop tumours that
metastasize to skin, liver, and bone marrow (<10% invasion).
4S tumours tend to disappear spontaneously without treat-
ment [62].
The tumour original site is not an independent prognostic
factor. The presence of typical histopathological features,
presence of tumour cells in a bone marrow aspirate/biopsy,
and raised concentration of urinary catecholamines further
conclude the development of neuroblastoma growth [58].
Cell-surface marker CD44, involved in cell-cell and cell-
matrix interactions, can be used as a diagnosticmarker for the
aggressiveness of cancer [5]. In low risk patients, the CD44 is
found expressed and thus enhanced the theory that with the
absence of N-myc amplification there is a favourable clinical
outcome [5].
3.3. Staging. Modifications of this latter classification system
reflected a need to classify neuroblastoma presurgically. The
International Neuroblastoma Risk Group (INRG) task force
developed a consensus for pretreatment risk stratification of
children with neuroblastoma. Cooperative groups of paedia-
tricians met in 2005 to work on classifying the tumour based
on imaging and bone marrow morphology rather than the
extent of surgical resection.The chart was obtained by a study
involving 11054 patients worldwide [60]. Stages L1 and L2
distinguish the regional tumours from involving just local
structures (L1) and from invading locally (L2).
The two major important clinical variables of neuroblas-
toma are the age and the stage at diagnosis [67]. In all the
stages of the disease higher than stage one, children of age
younger than 12months have had significantly better disease-
free survival rates than older children with equivalent stages
of disease [60].Monclair et al., on behalf of the INRG, suggest
that an age-at-diagnosis cut-off of greater than 18 months
is associated with greater risk of disease recurrence [60].
Another crucial point in staging and recurrence is the genetic
makeup of the developed neuroblastoma.
3.4. Genetic Aspects. Molecular abnormalities with regard to
neuroblastoma involve multiple genetic aberrations that give
rise to the heterogeneous features of this malignancy. Aggres-
siveness of the cancer phenotype can be related to loss
of tumour suppressor function that is an effect of loss of
genetic material or mutation in the responsive gene [4, 56].
Chromosomal abnormalities, in particular those involving
protooncogenes, are also responsible for uncontrolled growth
leading to the gain of protein function forcing cells to enter
cell cycle [4, 68]. The four majorly discussed genetic changes
in neuroblastoma are MYCN protooncogene amplification,
DNA content, and the allelic deletions on chromosomes
1p and 11q or the gain of 17q [62, 68, 69]. In addition,
activating mutation of the tyrosine kinase ALK (anaplastic
lymphoma kinase) was recently discovered in both familial
and sporadic neuroblastomas [70]. Studies showed familial
neuroblastoma displayed rarely, about 1-2% of the patients
with the incomplete inheritance of the autosomal dominant
pattern [70]. In such cases, this presents at an early age with
bilateral adrenal or multifocal primary tumours.
3.4.1. MYCN Amplification. The myc gene alteration is in-
volved persistently in various types of cancerous growth
and is regarded with the expression of multiple genes that
encode regulatory proteins [2]. Within this family of tran-
scriptional factors, two particular proteins are expressed by
N-myc gene section [71]. The role of this MYCN (N-myc)
gene in oncogenesis is thought to involve extrachromosomal
elements [72] or intrachromosomal homogeneously staining
regions [68]. A finding by Charron et al. concluded that
the regulation of the spatiotemporal gene expression of N-
myc during the development significantly regulated DNA
elements [73]. The amplification of such gene is evident in
most of the neuroblastoma rapidly progressive forms and
predicts a very poor prognosis irrespective of age and clinical
stage [74]. Furthermore, this was recorded in 20–25% of
primary neuroblastoma cases and about 40% of patients with
advanced disease [69].
3.4.2. Deletion or Allelic Loss of Chromosomes 1p and 11q.
Neuroblastoma occasionally presents with the unbalanced
deletions of the chromosome 1 short arm (1p) and that of
chromosome 11 long arm (11q23). This loss of heterozygosity
has been linked to less favourable clinical prognosis [74].
Contrasting the 1p deletion, the 11q23 elimination is inversely
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related to the MYCN amplification [75]. Furthermore, con-
clusions associated the presence of the 1p arm deletion with
advanced disease stage [74].
3.4.3. Gain in Chromosome 17q. Chromosomal gain aberra-
tions are also evident in neuroblastoma, such as the 17 long
arm gains. This particular unbalanced gain is associated with
adverse prognostic factors including stage 4 disease, MYCN
amplification, and thementioned aberration of chromosomes
1p and 11q [67].
3.4.4. DNA Ploidy. Furthermore, the DNA content is some-
times altered with occurrence of triploid and “near triploid”
accounting formore than half the cases of primary neuroblas-
toma.The remainder fraction cases are likely to have a defect
in genomic stability, resulting in chromosomal rearrange-
ments, unbalanced translocations, and deletions [59, 68].
3.5. Treatment. Management of the treatment for neuroblas-
toma includes themultimodal therapy of surgery, chemother-
apy, radiotherapy, and biotherapy [67]. Prior to treatment,
the paediatric oncologist classifies the case into a risk group
to follow the appropriate treatment. The Children Oncology
Group resolved these criteria through “TheRisk Stratification
System” that incorporates the patient age at diagnosis and
INSS stage as mentioned above, as well as tumour histopa-
thology, DNA index, and MYCN gene status [60]. Collec-
tively, these features will aid in assigning the patient under
one of these three stages: low, intermediate, or high-risk. Cis-
platin, etoposide, doxorubicin, and cyclophosphamide drugs
are commonly used in chemotherapy management for neu-
roblastoma.
4. Mechanisms of Chemoresistance by
Chemotherapeutic Drugs
Cytotoxic drugs target cells that are actively proliferating,
suggesting that they are progressing through the active phases
of the cell cycle. Although cytotoxic drugs are effective in
multiple cancer models, specific drugs target unique stages
in the cell cycle and therefore the choice of drug depends on
the molecular features of the cancer condition [76].
A typical example in breast cancer treatment would be a
therapy of a HER-2 positive breast cancer, where the aim is
to diminish the amplification of the receptor. Alternatively,
since BRCA genes play a fundamental role in repairing DNA
damage, treating a mutated BRCA malignancy must deal
with proteins involved in DNA repair that are not being
properly repaired by the BRCA protein products [77]. The
following sections focus on describing the two most utilized
chemotherapeutic agents for NB chemotherapy, namely, dox-
orubicin and etoposide.
4.1. Chemoresistance. Individual types of cancer have been
found to be extremely responsive to treatment at first but
then become noncompliant to therapy, a phenomenon that is
associated with chemoresistance [78].This can be considered
as the inability of the drug to induce its cytotoxic effect to
its maximum potential. Multiple cellular compartments are
responsible for this occurrence and various mechanisms can
be initiated by individual tumour cells at particular timef-
rames during the development of cancerous growth [55].
Membrane glycoproteins, tyrosine kinases, and growth factor
receptors all contribute to the development of a drug resistant
phenotype [79].
Resistance can be classified as either innate or acquired
[79]. Innate resistance develops from factors that are inherent
with the individual patient, such as genetic mutations within
particular genes [79]. As a case in point, breast cancer cases,
which commonly have a poor prognosis as a result of treat-
ment ineffectiveness, have been corroborated to HER gene
overexpression by Rexer and Arteaga, possibly due to intrin-
sic mechanisms against HER-2 targeted therapy [80]. On
the other hand, acquired chemoresistance progresses during
prolonged drug exposure by developing a drug resistant
phenotype [79].
Chemoresistance is noted to develop against a plethora of
drugs regardless of diverse chemical structures and different
mechanisms of intracellular activity, known as multidrug
resistance (MDR) [81]. The most fundamental mechanisms
causing MDR in tumour cells can be classified into non-
classical MDR and transport-based classical MDR [82]. The
nonclassical MDR includes alterations of enzyme systems
activity that reduce the targeted activity of the drug [82].
A typical example is glutathione S-transferase, an important
enzyme responsible for xenobiotic excretion [82]. Increased
activity of this enzyme has been seen in various drug resist-
ant MCF-7 breast cancer cell lines [83, 84]. Another type
of nonclassical MDR defect arises from an imbalance of
antiapoptotic and proapoptotic proteins causing alterations
in cell death signaling pathways and thus inhibition of apop-
tosis [85]. The classical cellular mechanisms of MDR involve
insignificant cellular uptake of the drug [86] and an increase
in the efflux of the drug due to an augmentation in the
expression of ATP-binding cassette proteins, reducing the
drug to insignificant doses [87].
Particularly in breast cancer, the key ABC transporters
involved in drug resistance include the P-glycoprotein (PGP),
multidrug resistance-associated protein 1 (MRP1), and the
breast cancer resistance protein (BCRP) [88]. The PGP was
the initial transporter found to be abundantly expressed in
breast cancer cell lines exhibiting MDR [89]. PGP acts on a
variety of substrates, such as cytotoxic agents in tumour cells
[90]. Studies validated that an increase in PGP expression has
been found in a substantial amount of breast cancer patients,
with a further increase in expression following treatment
with chemotherapeutic drugs [90]. PGP is responsible for
the transport of both neutral and cationic hydrophobic com-
pounds, including doxorubicin and etoposide [91].The efflux
of substances out of cells is powered by two ATP molecules
which fit in PGP’s two ATP-binding domains [91].
MRP1 is another transporter protein that is highly
expressed in a number of sites including breast tissue [92].
MRP1 also requires two molecules of ATP to actively pump
substances out of cells [91]. Likewise, studies have validated
that an augmentation in the expression of MRP1 develops
resistance to various cytotoxic drugs, including doxorubicin
[93].
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The breast cancer resistance protein (BRCP) has also been
found in a number of malignancies and similar to other pro-
teins, it is linked with chemoresistance to a spectrum of cyto-
toxic agents, including doxorubicin and etoposide, amongst
others [94]. However, unlike the other two transporters,
BRCP has only one nucleotide binding domain, meaning that
a single molecule of ATP is sufficient to transport substances
out of the cells [91].
5. miRNAs
The introduction of RNA interference (RNAi) technology in
the 1990s gave a new insight into factors affecting gene regu-
latory processes. Noncoding sequences of the transcriptome
have been in fact found to play major roles in gene regulation
[95].
Novel research has been linking the behavior of microR-
NAs (miRNAs) with having a crucial contribution to the
development of cancer which have lately been identified as
chief regulators of specific genes that are responsible for the
mechanisms initiating chemoresistance [96, 97].
MiRNAs are noncoding ribonucleic acids (RNAs) of
approximately 22 base pairs in size originating within the cell
and function as chief regulators in gene expression [98].Their
role takes place posttranscriptionally by bindingwithmRNAs
within genes, forcing suppression of translation [86].
5.1. Mechanism of miRNAs. Primary miRNAs (pri-miRNAs)
are the initial transcribed formofmiRNAs [99] and are in fact
approximately 70 nucleotides long [100]. Pri-miRNAs have a
methylated cap at the 5󸀠 end and polyadenylation at the 3󸀠 end
[101]. These then form distinctive hairpin-shaped stem-loop
secondary structures and associate with a microprocessor
complex comprised ofDrosha, which is an RNase III endonu-
clease, and cofactor DGCR8/Pasha, which is a protein having
two double-stranded RNA binding domains [102]. Within
this complex, these hairpin-shaped pri-miRNAs are pro-
cessed into 60–70 nucleotide pre-miRNAs and transported
into the cytoplasm via Exportin-5 [103, 104]. Once they reach
the cytoplasm, pre-miRNAs are converted to a short miRNA
duplex by another RNase III endonuclease, Dicer [105]. One
strand of this duplex is the final mature miRNA which can
then enter the RNA-induced silencing complex (RISC) and
guides RISC to the target mRNAs [106].
This complex is directed to the target mRNA via com-
plementary base pairing with the single-strand miRNA com-
prised within the complex [107]. Once the miRNA is taken
up by the RISC, the complex that is formed attaches to the
3󸀠 untranslated region (UTR) of the targetedmRNA, resulting
in posttranscriptional gene silencing by impeding translation
of the ribosome [108]. The overall effect of this complex
results in either (i) translational suppression, (ii) messenger
RNA (mRNA) degradation, or (iii) site-specific cleavage
[108].These mechanisms thereby result in gene silencing and
are carried out by Argonaute proteins [109]. Two Argonaute
(Ago) proteins, Ago 1 and 2 belonging to the Argonaute
family of proteins, have been identified as the main catalytic
endonucleases in human RISC [109, 110].
Numerous studies have associated dysregulated behavior
of miRNAs with a number of conditions, particularly cancer
[10, 79, 86, 111–114]. Calin et al. validated that at least half
of the miRNA genes are found in cancer-associated genomic
regions [115] thereby indicating that miRNAs have a crucial
responsibility in the development of a range of malignancies.
5.2. Role of miRNAs in Tumourigenesis. Upon assessing the
levels of miRNA in tumour tissue against normal tissue,
studies established that many of the miRNAs are abnormally
expressed in tumour cells, thereby leading to aberrant control
and production of its target mRNA [116]. Although not all
of the identified miRNAs contribute to the oncogenic pheno-
type, many of them are found to play a direct role [116, 117].
Their aberrant behavior is apparent in a number of cancers,
demonstrating that they can take the role of oncogenic or
tumour suppressor miRNAs [116].
If miRNAs are found to be upregulated in cancer cells,
significant downregulation of their target genes would result.
These target genes can have an impact in both cellular path-
ways and genes that control the stimulation and progression
of a disease. The miRNAs that are upregulated are termed as
oncogenic miRNAs (oncomirs) and can target tumour sup-
pressor genes, causing significant downregulation of tumour
suppressors, such that their function in maintaining normal
cellular control is disrupted [114]. Specifically, Jiang et al.
identified the augmented expression of miR-155 in breast
cancer cells, where MCF-7 cells were in fact stimulated to
grow three times as much [118]. Another typical oncogenic
miRNA is miR-21 where its upregulation has been associated
with resistant breast cancer cells [10]. The target of miR-21
is the phosphate and tensin homolog (PTEN) tumour sup-
pressor gene which in turn activates the PKI3/AKt pathway
that triggers cellular apoptosis [10]. Abnormal silencing of
the PTEN gene will result in diminished apoptosis allowing
abnormal cellular proliferation [10].
The opposite effect occurs by tumour suppressormiRNAs
where their abnormal downregulation results in upregulation
of their target oncogenes.The role of oncogeneswill be hugely
intensified such that the cells receive continuous growth
signals, allowing abnormal cell proliferation [114]. One par-
ticular tumour suppressor miRNA, miR-205, has been found
to be substantially reduced in four different breast cancer cell
lines when compared to healthy breast cells [119]. Lorio et
al. established that miR-205 targets the receptor of the HER3
oncogene. Downregulation of miR-205 in cancer cells will
result in an elevated expression of the HER3 which stimulates
aggressive tumour growth [120].
Development and progression of cancer are influenced by
whether such key miRNAs are highly or poorly expressed,
indicating that a tumor may form due to upregulation of an
oncogenic miRNA or the downregulation of a tumour sup-
pressor miRNA or both in tandem.
5.3. Role of miRNAs in Tumour Metastasis. Apart from
enhancing tumor proliferation, miRNAs are also linked with
tumor metastasis, if their target genes are correlated with the
metastatic phenotype of cancer cells [121]. Significantly, miR-
10b is the prominent miRNA that has been found to have
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a metastasis-promoting effect [122]. MiR-10b has been iden-
tified as the target of an oncoprotein that enables epithelial-
mesenchymal transition (EMT), Twist1 [113]. EMT is a crucial
process in the metastatic cascade that is denoted by cells
acquiring migratory and invasive properties following a loss
of cell-cell junctions and cellular polarity [123]. Current stud-
ies validated the overexpression of Twist1 in metastatic breast
cancer cells, which thereby causes an amplified expression
of miR-10b [122]. Han et al. established a link between the
stimulation of miR-10b and the TGF-𝛽1 signaling pathway,
where the overexpression of miR-10b in breast cancer cells
and tissues was found to be overexpressed [123]. Further-
more, the level of augmented expression was also found to be
highly related to breast cancer aggressiveness [123]. Potential
inhibition of miR-10b could serve as an effective target to
deter metastasis and treat breast cancer due to the partial
inhibition of TGF-𝛽1 induced proliferation and EMT [123].
5.4. miRNAs Linked with Chemoresistance in Cancer Cells.
These short noncoding RNAs emerged as key posttranscrip-
tional regulators of gene expression. Consequently, their dys-
regulation may lead to abnormal gene expression, seen evi-
dently in the regulation of certain pathways [124].
Anunderlying cause ofmultidrug resistance (MDR) is the
overexpression of one or more of the ATP binding cassette
transporters [79]. Through the work of Bao et al., it was
found that miR-298 complemented the 3󸀠UTR of one of these
transporters, P-glycoprotein (P-gp) mRNA [125]. Through
the same study, chemoresistant developed cell lines expressed
a depression in this miRNA level, enhancing even more the
evidence that P-pg upregulation is inducing chemoresistance
[125]. Moreover, it also concluded that miR-298 is truly
responsible for the suppression of P-gp [125]. The latter
literature was based on breast cell line; howbeit [126] reported
upregulation of miR-27a and miR-451 in two parent cell lines
that were also MDR. In such case the miRNAs upregulation
was correlated with the increased expression of P-gp and
MDR1 mRNA translation [126].
Failure of cells to enter the apoptosis pathway is one of the
methods of chemoresistance [127, 128]. In turn, recent studies
showed the involvement of miRNAs to regulate apoptosis by
the interaction with such mRNAs.
The death-inducing signalling complex (DISC) plays an
important role in such regulation of apoptosis pathway [129].
The TRAIL-induced apoptosis pathway that is related to this
DISC complex is evidently affected by the level of miRNAs
[130].ThemiR-221 andmiR-222were found to be upregulated
in TRAIL resistant cells while downregulated in sensitive cells
[131]. The study revealed that when treating the TRAIL resis-
tant cells with anti-miRNA for mentioned miR-221 and miR-
222, the cells regained their sensitivity towards drugs [131].
AKT-dependent pathway regulates cell processed by
mediating extracellular and intracellular signals [132, 133].
The Akt pathway potentially acts as antiapoptotic pathway
that requires the presence of miR-21 to employ the chem-
oresistant effect [132].The relationship was found in glioblas-
toma cells lines, where the apoptotic process was restored
after inhibition of this miR-21 [134].
In another study,miR-200c inhibits the apoptosis induced
by Fas-associated phosphatase-1 (FAP-1), acting as an anti-
apoptotic miRNA [135]. Moreover, evidence even proved that
miR-200c is involved in the activation of the mentioned Akt
signalling pathway [136].
Conversely, protoapoptotic miRNAs level is significantly
lower in apoptotic pathway induced chemoresistance [137].
MiR-34 knockdown has been linked to resistance to apopto-
sis, with a further link done to the activation of p53 [137, 138].
Furthermore, BCL-2 protein is considered an antiapoptotic
protein that is downregulated by miR-34 [139].
Other evidence proved that overexpression of miR-140
causes chemoresistance in human osteosarcoma and colon
cancer cells [140]. In both cases, the cell lines were of wild-
type p53 [140].
5.5. MicroRNA in Neuroblastoma. Studies on neuroblastoma
also revealed a pattern of miRNA dysregulation upon certain
mutations that consequently lead to chemoresistance [124,
141, 142]. The study by Bray et al. showed evidence that in
MYCN amplified neuroblastoma cell lines, seven miRNAs
were significantly over- or underexpressed relative to single
MYCN copy tumour cells. Secondly, the study also concluded
that in large chromosomal imbalances of neuroblastoma cell
line, suchmiRNAdysregulationwas involved [141]. Chen and
Stallings were able to indicate that miR-184 has a significant
role in the apoptosis of neuroblastoma with suggestions that
MYCN also mediates tumorigenic effect by regulating the
miRNAs [142].
Recently, in 2012 the miR-21 oncomir was identified to
have an effect on chemoresistance in neuroblastoma [143].
Cell lines in this study were rendered resistant to cisplatin
where the level of expression of miR-21 was proven to be
elevated when compared to sensitive cell lines. Chen et al.
analyzed this effect through the sensitivity towards drugs
that these cells obtain following miR-21 inhibition. In further
literature, the MYCN gene was knocked down in neuroblas-
toma cells, with a subsequence upregulation of the miR-21,
concluding an inversely proportional relationship [144].
5.6. Association of miRNAs with Breast Cancer. A relatively
good amount of miRNAs has been linked with breast cancer
in particular (see Table 2). Depending on the gene they target,
miRNAs can either affect cellular mechanisms allowing
abnormal growth, promote metastasis, or play a crucial role
in the development of a drug resistant phenotype. Apart from
worsening the prognosis, their abnormal behavior also ceases
the effect of therapy, leading to the challenging chemoresis-
tance issue described earlier.
In point of fact, Singh and Mo investigated 76 breast
cancer and 10 normal breast sampleswhere 29miRNAswhere
found to be abnormally expressed, miR-125b, miR-145, miR-
21, and miR-155 being the mostly dysregulated [145].
O’Driscoll andClynes certified that acquired and intrinsic
chemoresistance causes treatment to be unsuccessful in at
least one of two breast cancer patients [146]. Considering
that aberrant behaviour of miRNAs does play a role in tum-
ourigenesis and development of chemoresistance, stabilizing
this aberrant behavior of miRNAs can serve as a therapeutic
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Table 2: miRNAs found to be associated with breast cancer and their respective target genes.
miRNA Dysregulated expression Target genes References
miR-10a Upregulated Hox genes [152, 153]
miR-21 Upregulated PTEN, PDCD4 [154, 155]
miR-29a Upregulated PTEN [155, 156]
miR-125b Upregulated E2F3 [155, 157]
miR-203 Upregulated SOC3 [158]
miR-210 Upregulated Efna3 [159]
miR-222 Upregulated PTEN [155, 157]
miR-30c Downregulated TWF I [160]
miR-31 Downregulated PKC epsilon [161]
miR-34a Downregulated NOTCHI [162]
miR-93 Downregulated TGF𝛽R2 [101, 155]
miR-128 Downregulated BMII, ABCC5 [163]
miR-137 Downregulated Pgp indirectly [164]
miR-205 Downregulated HMGB3 [119, 155]
miR-200a and 200b Downregulated ZEB 1/2 [155, 165]
miR-200c Downregulated ZEB I, CDH I, PTEN [155, 166, 167]
miR-298 Downregulated MDR (P-gp) [168]
miR-487a Downregulated ABCG2 (BRCP) [169]
PDCD4: programmed cell death 4, E2F3: E2F transcription factor 3, SOC3: suppressor of cytokine signalling 3, Efna3: ephrin A3, TWF I: twinfilin actin-
binding protein I, PKC: protein kinase C, TGF𝛽R2: transforming growth factor-𝛽 receptor II, ABCC5: ATP-binding cassette, Subfamily CMember 5, HMGB3:
high mobility group box 3, ZEB: zinc finger E-box, CDH: cadherin, and ABCG2: ATP-binding cassette, Subfamily G Member 2.
potential for a wide spread cancer condition like breast can-
cer.
DevelopingmiRNA-targeted therapeutics depends on the
genes the miRNA in question targets, such that miRNA
antagonists can be used to regulate gain-of-functionmiRNAs,
whereasmiRNAmimics can be used to enhance loss-of-func-
tion miRNAs. A miRNA antagonist, anti-miR, is an exten-
sively chemically modified miRNA passenger strand which
has a high affinity for the miRNA strand [116]. The binding
generated between the two is usually significantly strong such
that it is quite irreversible, resulting in a stablemiRNAduplex
that cannot be processed and thereby degraded by RISC [116].
As a result, extensive silencing of the target gene is reduced.
Conversely, miRNA mimics, miR-mimic, function by
triggering gene silencing. miR-mimics are developed by arti-
ficial double-stranded miRNA-like RNA fragments [147].
Specifically, this RNA fragment is generated with a free 5󸀠 end
which has a partially complementary sequence to the 3󸀠-UTR
sequence of the target gene [147]. This artificial miRNA
behaves like the endogenousmiRNA and specifically binds to
the target gene and inhibits translation posttranscriptionally
[147].With reference to the downregulation ofmiR-451which
is associated with multidrug resistance, a miR-mimic was
found to make up for the loss of gene silencing [148].
Kovalchuk et al. validated that transfection of doxorubicin-
resistant cells with commercially prepared miR-451 resulted
in improved sensitivity to doxorubicin [148]. This signi-
fies that upregulation of the reduced miRNA expression
improved the sensitivity of the cells.This crucial principle can
serve as a potential method to overcome the highly emerg-
ing problem of chemoresistance and limit tumour growth,
leading to improvement of the outcome.
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